|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Biogen-IDEC: PharmaVitae Profile 2005 |
|
|
|
|
€ 4 845,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2005 |
Taille du document : |
76 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment
148 pages | |
Obesity Drug Markets in the US and EUAnalysis of product pipelines and competitive environmentBusiness Intelligence for the Pharmaceutical IndustryBusiness Insights' portfolio of healthcare management |
3 068,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval
113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
MarketWatch: Biotechnology
32 pages | |
Datamonitor's Biotechnology MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the Biotechnology industry.
The report contains th |
160,00 €
|
| |
| |
Commercial and Pipeline Insight: Fibromyalgia - Approvals legitimize condition and expose underserved patient population
193 pages | |
IntroductionWith a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies.
Estimated to total |
12 160,00 €
|
| |
| |
Commercial and Pipeline Insight: Vaccines for Adults and the Elderly - New blockbuster opportunities ahead
161 pages | |
IntroductionVaccines have re-emerged as successful revenue generators for Big Pharma, with adults and the elderly now increasingly coming into focus as the next big opportunity in this sector.
An a |
12 320,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets
214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals.
Mar |
795,00 €
|
| |
| |
The Pharmaceutical Outsourcing Outlook 1998-2003
199 pages | Juin 1999 |
The streamlining of pharmaceutical companies that has taken place in recent years has allowed them to focus resources and investment on core specialities.
This, in turn, has led to a greater re |
795,00 €
|
| |
| |
Healthcare In Scotland
52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
Global Pharmaceutical: a market, company and disease analysis
150 pages | Octobre 1998 |
What will drive pharmaceutical market growth into the 21st Century? What are the key challenges facing pharmaceutical manufacturers? Who are the market leaders in each sector? What strategies ar |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Biogen-IDEC: PharmaVitae Profile 2005 |
|
|
Introduction
This company analysis examines the current position and future outlook for Biogen-IDEC in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Biogen-IDEC's performance against key rivals in the ethical pharmaceutical sector
Learn of the steps Biogen-IDEC has taken to mitigate the financial impact of Tysabri's withdrawal
|
|
Introduction
This company analysis examines the current position and future outlook for Biogen-IDEC in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Biogen-IDEC's performance against key rivals in the ethical pharmaceutical sector
Learn of the steps Biogen-IDEC has taken to mitigate the financial impact of Tysabri's withdrawal
|
|
|
PPLSEN
|
|
|
|
|
